LB Pharmaceuticals logo

LB Pharmaceuticals

LBRX | NASDAQ
Chart Builder DCF Calculator
$42.99
-$0.02 (-0.05%)
At close: Nov 16, 2026, 4:00 PM ET
$42.99
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.05%

Rating

Updated: Nov 16, 2026
29
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #833/1021 (Top 82%)

Key Statistics

Market Data

Market Cap $1.39B
1D Range
42.08 43.95
52W Range
15.33 49.48

Valuation (TTM)

PE -9.31
PB 3.33
EV/EBITDA -12.29

Valuation (NTM)

Forward PE N/A
Forward PEG -0.18
Price Target $60.00
Loading financial charts...

Profile

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depr...

Sector Healthcare
Industry Biotechnology
Employees 49
IPO Date Sep 11, 2025
Website lbpharma.us
Fiscal Year January - December

Latest News

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

20 days ago · marketbeat.com

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
LB Pharmaceuticals to Participate in Upcoming Investor Events

1 month ago · globenewswire.com

LB Pharmaceuticals to Participate in Upcoming Investor Events
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity

2 months ago · seekingalpha.com

LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.

2 months ago · globenewswire.com

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
LB Pharmaceuticals to Participate in Upcoming September Investor Events

2 months ago · globenewswire.com

LB Pharmaceuticals to Participate in Upcoming September Investor Events
LB Pharmaceuticals Announces $150 Million Private Placement

4 months ago · globenewswire.com

LB Pharmaceuticals Announces $150 Million Private Placement

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$60.00
Upside
+39.57%
Buy (3)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.